Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for Staphylococcus aureus In Vivo Infection.

Area of Science:

• Nanotechnology
• Pharmacology
• Microbiology

Background:

• Antibiotic resistance in bacteria like Staphylococcus aureus necessitates novel treatment strategies.
• Cubosomes offer a nanotechnology-based delivery system with potential for enhanced antibacterial action.

Purpose of the Study:

• To encapsulate celecoxib into cubosomal nanoparticles for improved antibacterial efficacy.
• To evaluate the in vitro characteristics and in vivo antibacterial activity of celecoxib-loaded cubosomes against Staphylococcus aureus.

Main Methods:

• Celecoxib encapsulation into cubosomes, followed by in vitro characterization (size, zeta potential, entrapment efficiency, release).
• In vivo assessment using a systemic infection model in mice, including tissue analysis (histopathology, immunostaining) and measurement of inflammatory markers.

Main Results:

• Celecoxib-loaded cubosomes exhibited favorable physicochemical properties (mean size 128.15 nm, negative zeta potential -17.50, entrapment efficiency 88.57%).
• In vivo studies demonstrated reduced bacterial burden, inflammation, and apoptosis in liver and spleen tissues of treated mice.
• Significant decrease in inflammatory markers (IL-1β, IL-6, COX-2, TNF-α) was observed, indicating effective modulation of inflammatory pathways.

Conclusions:

• Cubosomes represent a promising drug delivery system for celecoxib, enhancing its in vivo antibacterial activity.
• This formulation improves oral bioavailability and efficacy against Gram-positive bacterial infections.